Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826)
Hong Kong
· Delayed Price · Currency is HKD
25.60
0.00 (0.00%)
Jan 3, 2025, 4:08 PM HKT
Shanghai Haohai Biological Technology Revenue
Shanghai Haohai Biological Technology had revenue of 670.37M CNY in the quarter ending September 30, 2024, with 0.22% growth. This brings the company's revenue in the last twelve months to 2.75B, up 8.60% year-over-year. In the year 2023, Shanghai Haohai Biological Technology had annual revenue of 2.65B with 24.59% growth.
Revenue (ttm)
2.75B CNY
Revenue Growth
+8.60%
P/S Ratio
2.77
Revenue / Employee
1.27M CNY
Employees
2,158
Market Cap
12.88B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.65B | 523.76M | 24.59% |
Dec 31, 2022 | 2.13B | 380.16M | 21.72% |
Dec 31, 2021 | 1.75B | 425.69M | 32.14% |
Dec 31, 2020 | 1.32B | -271.07M | -16.99% |
Dec 31, 2019 | 1.60B | 49.67M | 3.21% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Innovent Biologics | 8.01B |
Sino Biopharmaceutical | 29.86B |
CSPC Pharmaceutical Group | 33.53B |